Does cisplatin chemotherapy decrease the MDP uptake of normal bone? An experimental study

ÖZDOĞAN Ö., ERTAY T., Arslan G., Sisman A., ÇAPA KAYA G., YILMAZ O., ...More

ANNALS OF NUCLEAR MEDICINE, vol.22, no.5, pp.357-362, 2008 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 5
  • Publication Date: 2008
  • Doi Number: 10.1007/s12149-007-0129-5
  • Journal Name: ANNALS OF NUCLEAR MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.357-362
  • Keywords: cisplatin, Tc-99m MDP, bone scintigraphy, chemotherapy, bone uptake, CELL CARCINOMA, PHASE-II, COMBINATION, DIPHOSPHONATE, CARBOPLATIN, TOXICITY, PLATINUM, THERAPY, TC-99M, RAT
  • Dokuz Eylül University Affiliated: Yes

Abstract

Objective Bone scan is the accepted initial imaging modality for skeletal metastases. Cisplatin is a cell-cycle nonspecific antineoplastic agent used in some chemotherapy regimens. Knowing that platinum reacts with phosphate compounds such as methylenediphosphonic acid (MDP), decreases bone resorption and new bone formation, it can be proposed that cisplatin chemotherapy may decrease Tc-99m MDP bone uptake. We aimed to demonstrate, if present, the decrease in bone uptake and to determine the duration of this effect.